Related Experiment Videos
FHIT as tumor suppressor: mechanisms and therapeutic opportunities
Yuri Pekarsky1, Alexey Palamarchuk, Kay Huebner
1Kimmel Cancer Center; Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.
Abstract:
Chromosomal abnormalities including homozygous deletions and loss of heterozygosity at 3p l4.2 are commonly observed in most human tumors, including lung, breast and kidney cancers. This region also contains the most common human fragile site FRA3B, a familial kidney cancer-associated translocation breakpoint and papilloma virus integration sites. The FHIT gene is a tumor suppressor, which is frequently inactivated by mentioned genomic alterations at 3pl4.2. In the last few years considerable amount of data describing inactivation of FHIT in a variety of human malignancies and demonstrating the tumor suppressor potential of Fhit has accumulated. However, these have not yet led to major advances in uncovering the precise molecular mechanism of Fhit action. This review focuses on the most recent progress in understanding of Fhit function as a tumor suppressor and opportunities for gene cancer therapy with Fhit.
Insights
The FHIT gene, a tumor suppressor, is often inactivated in various cancers due to genomic alterations. Understanding Fhit
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Chromosomal abnormalities at 3p14.2, including deletions and loss of heterozygosity, are prevalent in human tumors like lung, breast, and kidney cancers.
- This critical region encompasses the common fragile site FRA3B, a translocation breakpoint linked to familial kidney cancer, and papillomavirus integration sites.
- The FHIT (Fragile Histidine Triad) gene, a known tumor suppressor, is frequently inactivated by these genomic alterations at 3p14.2.
Purpose of the Study:
- To review recent advancements in understanding the tumor suppressor functions of the FHIT gene.
- To explore the precise molecular mechanisms underlying Fhit's action in cancer suppression.
- To discuss potential therapeutic strategies for cancer gene therapy utilizing Fhit.
Main Methods:
- Literature review of recent studies on FHIT gene function and inactivation in malignancies.
- Analysis of data on genomic alterations at 3p14.2 and their impact on FHIT.
- Synthesis of findings related to Fhit's tumor suppressor activity and therapeutic potential.
Main Results:
- Accumulated evidence demonstrates FHIT inactivation in diverse human malignancies.
- The tumor suppressor potential of Fhit is well-established across various cancer types.
- Significant progress has been made in understanding Fhit's role, though precise molecular mechanisms require further elucidation.
Conclusions:
- FHIT gene inactivation is a common event in many cancers, highlighting its role as a tumor suppressor.
- Further research into the molecular mechanisms of Fhit action is crucial for developing effective cancer therapies.
- FHIT holds promise as a target for novel gene cancer therapy strategies.